MajorVitamin K antagonist anticoagulants×Analgesics and antipyretics. Pyrazolones
Updated · Methodology
Mechanism
Acenocoumarol is a coumarin derivative and vitamin K antagonist. Its interactions with other drugs act through absorption, through liver enzymes, mainly CYP2C9, and through the availability of vitamin K needed to activate clotting factors (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish acenocoumarol SmPCs, both the originator and a generic, list phenylbutazone and other pyrazolone derivatives among drugs that potentiate the anticoagulant effect or impair haemostasis and raise the risk of bleeding (acenocoumarol SmPCs, AEMPS). The metamizole SmPC classes metamizole as a pyrazolone. It states that pyrazolones may interact with oral anticoagulants, but it is not known to what extent this applies to metamizole itself (metamizole SmPC, AEMPS). Metamizole can also induce the enzymes CYP2B6 and CYP3A4 (metamizole SmPC, AEMPS), and CYP3A4 inducers may reduce the effect of acenocoumarol (acenocoumarol SmPCs, AEMPS). The documents do not say how large this effect is for this combination.
Symptoms
The main risk is bleeding. Acenocoumarol can cause serious bleeding, including haemorrhagic shock, and fatal bleeding. The risk is higher with an international normalised ratio (INR) above 4.0, at age 65 or older, with a history of gastrointestinal bleeding and with concomitant treatment (acenocoumarol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Gastrointestinal bleeding has been reported with metamizole. Many of these patients were also taking other drugs linked to such bleeding, for example non-steroidal anti-inflammatory drugs, or had taken an overdose of metamizole (metamizole SmPC, AEMPS). With metamizole, bruising, bleeding and pallor together with fever, sore throat and painful changes in the lining of the mouth or nose may signal a blood disorder. Agranulocytosis and thrombocytopenia occur very rarely (metamizole SmPC, AEMPS).
Management
The Spanish acenocoumarol SmPCs, both the originator and a generic, generally do not recommend combining acenocoumarol with pyrazolone derivatives unless the combination is strictly indicated (acenocoumarol summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The metamizole SmPC classes metamizole as a pyrazolone (metamizole SmPC, AEMPS). It adds that it is not known to what extent the interaction of pyrazolones with oral anticoagulants applies to metamizole itself (AEMPS). The acenocoumarol SmPCs make no such reservation (AEMPS). If metamizole cannot be avoided, use close and frequent coagulation checks, for example twice a week, both after metamizole is started and after it is stopped. While the two drugs are taken together, test the international normalised ratio (INR) more often than usual (acenocoumarol SmPCs, AEMPS). If bruising, bleeding, pallor, fever, sore throat or painful changes in the lining of the mouth appear, stop metamizole at once without waiting for laboratory results. Monitor the full blood count with differential until it returns to normal (metamizole SmPC, AEMPS). In older people and in renal or hepatic impairment, use metamizole only after weighing benefit and risk (metamizole SmPC, AEMPS). Use acenocoumarol with caution in mild to moderate renal or hepatic impairment (acenocoumarol SmPC, AEMPS). In significant bleeding, interrupt acenocoumarol and give 5–10 mg of vitamin K1 intravenously very slowly, no faster than 1 mg per minute (acenocoumarol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Metamizol, Nolotil 575 mg cápsulas (nº registro 47633), secciones 4.4 y 4.5 (2024)– AEMPS, CIMA, nº registro 47633, revisión 11/2024, secciones 4.4 y 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.5 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.5 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol Aurovitas 4 mg (nº registro 88315), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88315 (Acenocumarol Aurovitas 4 mg comprimidos EFG; texto idéntico en 1 mg, nº 88278), revisión 07/2025, sección 4.5
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.9 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.9 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.9
- AEMPS: Ficha técnica: Acenocumarol, Sintrom 4 mg (nº registro 25670), sección 4.4 (2025)– AEMPS, CIMA, nº registro 25670 (Sintrom 4 mg comprimidos, Merus Labs; texto de la sección 4.4 idéntico en Sintrom 1 mg, nº 58994), revisión 06/2025, sección 4.4
- AEMPS: Ficha técnica: Metamizol, Nolotil 575 mg cápsulas (nº registro 47633), secciones 4.3 y 5.1 (2024)– AEMPS, CIMA, nº registro 47633 (Nolotil 575 mg cápsulas duras, Boehringer Ingelheim España), revisión 12/2024, secciones 4.3 y 5.1 (grupo farmacoterapéutico: pirazolonas)